The Chase Group is pleased to announce the successful completion of the Vice President, Medical Affairs search for Avidity Biosciences. Nathan Weedin brings 15+ years of experience to the position and will be responsible for creating and building the global medical affairs function. Avidity’s platform is first-in-class technology of antibody-oligonucleotide conjugates that can effectively deliver oligonucleotides tissues other than the liver, which has not previously been possible. The Chase Group values the partnership with Steve Hughes, CMO, and congratulates Avidity on securing an exceptional executive for the team. For more information on how The Chase Group can assist your company by placing entrepreneurial leaders to transform bold ideas into breakthrough medical discoveries, email karen@chasegroup.com.
Successful Placement at Avidity
The Chase Group is pleased to announce the successful completion of the Vice President, Medical Affairs search for Avidity Biosciences. Nathan Weedin brings 15+ years of experience to the position and will be responsible for creating and building the global medical affairs function. Avidity’s platform is first-in-class technology of antibody-oligonucleotide conjugates that can effectively deliver oligonucleotides tissues other than the liver, which has not previously been possible. The Chase Group values the partnership with Steve Hughes, CMO, and congratulates Avidity on securing an exceptional executive for the team. For more information on how The Chase Group can assist your company by placing entrepreneurial leaders to transform bold ideas into breakthrough medical discoveries, email karen@chasegroup.com.
Ionis Director, Global HEOR, Rare Disease Immunology, Successfully Placed by The Chase Group
Ami Claxton, MS, PhD has joined Ionis Pharmaceuticals, Inc. as Director, Global HEOR Rare Disease Immunology. She will play a critical and significant role as…-
Successful Placement at Avidity
The Chase Group is pleased to announce the successful completion of the Vice President, Medical Affairs search for Avidity Biosciences. Nathan Weedin brings 15+ years… 
The Chase Group Successfully Completes Search for Amyloidosis Medical Affairs Leader
Ionis Pharmaceuticals has a 35-year track record of perfecting and advancing RNA-targeted drug discovery and development. Projecting a vast number of new transformational products on…
The Chase Group Identifies Chief Medical Officer for Arcturus Therapeutics
In late 2022, Arcturus Therapeutics retained The Chase Group to build out additions to the leadership team. Tasked with identifying the new Chief Medical Officer,…
The Chase Group Secures VP, Head of Regulatory Affairs, for Checkmate Pharmaceuticals
The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate…
The Chase Group Secures Teng Jin Ong for Genmab
Amid an era of rapid growth, Genmab retained The Chase Group to secure a new clinical development medical executive as they work to pioneer the…